Real-world use of efgartigimod in acetylcholine receptor antibody–positive generalized myasthenia gravis: experience from two centers in Greece and Cyprus

IntroductionEfgartigimod, an FcRn antagonist that reduces circulating immunoglobulin G (IgG), is approved for the treatment of acetylcholine receptor (AChR) antibody–positive generalized myasthenia gravis (gMG). While its efficacy has been demonstrated in randomized clinical trials, real-world data...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Tasos Tsokkos, Eleni Strataki, Dimitra Tzavella, Eleni Zamba-Papanicolaou, Kleopas A. Kleopa, Vasiliki Zouvelou
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2026-01-01
Saila:	Frontiers in Neurology
Gaiak:	AChR-positive MG corticosteroid tapering efgartigimod FcRn inhibition generalized myasthenia gravis longitudinal management
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fneur.2026.1755374/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!